BiotechTube

Cancer

29 competing products in clinical development for Cancer.

Pipeline by Phase

Pre-clinical1
Phase 117
Phase 1/21
Phase 26
Phase 32
Approved2

All Products (29)

ProductCompanyStageStatusHype
ramosetron, aprepitant, dexamethasone + palonosetron, aprepitant, dexamethasoneAstellas PharmaApprovedCompleted
43
Panitumumab + Olaparib + Dabrafenib + Nilotinib + Trametinib + Erlotinib + Trastuzumab and Pertuzumab (combination treatment) + Vemurafenib and Cobimetinib (combination treatment) + Vismodegib + Regorafenib + Nivolumab + Afatinib + Dabrafenib and trametinib + Ribociclib + Lenvatinib + Pembrolizumab + Durvalumab + Rucaparib + Axitinib + Palbociclib + Crizotinib + Sunitinib + Cabozantinib + Abemaciclib + Alectinib + Atezolizumab and Bevacizumab + Ipilimumab and nivolumab + Entrectinib + Talazoparib + Dacomitinib + Lorlatinib + Erdafitinib + Alpelisib + Niraparib + Pemigatinib + Selpercatinib + TepotinibEisaiPhase 2Recruiting
42
Denosumab + Zoledronic acid + Placebo to Denosumab + Placebo to zoledronic acid + Denosumab (for the open-label treatment phase)Daiichi SankyoPhase 3Completed
40
PanitumumabAmgenApprovedUNKNOWN
39
ramosetron + ondansetronAstellas PharmaPhase 3UNKNOWN
36
Bevacizumab + Cetuximab + PemetrexedEli LillyPhase 2Completed
35
Eribulin + LenvatinibEisaiPhase 2Completed
35
E7107EisaiPhase 1Active
33
E7107EisaiPhase 1Active
33
E7389EisaiPhase 1Completed
29
LY3300054 + PrexasertibEli LillyPhase 1Completed
29
YM155Astellas PharmaPhase 1Completed
29
MORAb-009EisaiPhase 1Completed
29
E7050EisaiPhase 1Completed
29
E7389 + E7389 + E7389EisaiPhase 1Completed
29
E7070 + irinotecan combination + Irinotecan + E7070 combination + Irinotecan + E7070 combinationEisaiPhase 1Completed
29
HOPE + HOPEEisaiPhase 1Completed
29
E7080EisaiPhase 1Completed
29
E7389 + carboplatin AUC 5 + E7389 + carboplatin AUC 6 + E7389+carboplatin AUC 6EisaiPhase 1Completed
29
E7389EisaiPhase 1Completed
29
Eribulin alone + Eribulin plus KetoconazoleEisaiPhase 1Completed
29
ARQ197Kyowa KirinPhase 1Completed
29
Relatlimab + NivolumabOno PharmaceuticalPhase 1Completed
29
VeliparibAbbViePhase 2Withdrawn
27
LenvatinibEisaiPhase 2Withdrawn
27
XL820ExelixisPhase 1Completed
26
Denileukin diftitox (ONTAK)EisaiPre-clinicalCompleted
26
Fludarabine (Conditional therapy) + Cyclophosphamide Monohydrate (Conditional therapy) + firi-cel (Experimental drug)CARGO TherapeuticsPhase 2Terminated
17
eFT508eFFECTOR TherapeuticsPhase 1/2Terminated
14